Premium
Stigmasterol solid‐lipid nanoparticle development for lung cancer therapy
Author(s) -
Torres Zally,
Delgado Yamixa,
Griebenow Kai
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.lb92
Subject(s) - stigmasterol , solid lipid nanoparticle , chemistry , pharmacology , cytotoxicity , drug delivery , drug , cancer , biochemistry , cancer research , biophysics , in vitro , medicine , biology , chromatography , organic chemistry
Development of new therapies for lung cancer using nano‐formulations has become strategy to minimize the lack of drug inactivation after administration into patients. An alternative to increasing the effectiveness of the drugs is by development of drug delivery systems using solid‐lipid nanoparticles (SLN). Stigmasterol (Stg), an unsaturated phytosterol found in plant oils, has shown potent anti‐carcinogenic properties. Herein, we developed a Stigmasterol‐SLNs (~200 nm and polydispersity index value of 0.2) nano‐formulation by use of a microemulsion method. This size is compatible with tumor accumulation through the irregular vasculature observed in cancer tissues. Our system demonstrates strong cytotoxicity in lung cancer A549 cells with an IC 50 of 11 μM after 24 h. The mechanism of action of the Stg‐SNL has been confirmed to involve activation of caspase‐3/7 by extracellular assay. In addition, the established involvement of oxidative stress by determining reduced glutathione levels. The mechanism is necrosis independent. Physical stability of the Stg‐SLN formulation in the liquid phase was investigated by incubation at 37ºC by for three days and was maintained. More in vitro studies will be completed to confirm the selectivity of Stg‐SLN. In conclusion, we have designed a system for phytosterol delivery from nanoparticles with low poly‐dispersity which potentially could accumulate in cancerous tissues. Support or Funding Information NIH grant (RISE): 5R25GM061151‐16 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .